FDA/CDER SBIA Chronicles, the bi-monthly newsletter of the CDER Small Business and Industry Assistance team, provides industry with useful information to assist in all aspects of drug marketing and regulation
Similar Posts
Resources for Biomarker Requestors
Information and resources for requestors about FDA’s Biomarker Qualification ProgramKVK-Tech, Inc. Issues Voluntary Nationwide Recall of One Lot of Betaxolol Tablets, USP 10 mg (Batch Number: 17853A) as a Precautionary Measure Due to a Single Foreign Tablet Found During the Line Clearance After the Batch was Packaged
Newtown, Pennsylvania, KVK-Tech, Inc. is voluntarily recalling one lot (Batch Number: 17853A; “the batch”) of Betaxolol Tablets, USP 10 mg, White, Round, film coated biconvex tablets, debossed “K” above bisect “13” on one side and plain on the other side” to the consumer level. The batch was distribWithdrawn | Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
This listing includes accelerated approvals (AAs) for non-malignant hematological, neurological, and other disorder indications with postmarketing trials that have been subsequently withdrawn, and are therefore, no longer FDA-approved.CPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections
ORA and CDER agree to replace and/or withdraw CPGs in favor of using guidance or procedural documents, as appropriate per GGP regulations.MOLOOCO dba Ourlyard – Online Advisory Letter
MOLOOCO dba Ourlyard – Online Advisory LetterHTO Nevada, Inc. dba Kirkman – 719074 – 01/27/2026
CGMP/Finished Pharmaceuticals/Adulterated